Following on from information provided to NICE by the company in February 2013, the appraisal of Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 415 |
| Referral date | 01 September 2011 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | Kate Moore |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2013, the appraisal of Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 5 February 2013 |
NICE have been informed by the manufacturer of ridaforolimus that the Marketing Authorisation application for ridaforolimus with the EMA has been withdrawn. View further information. This appraisal consequently remains suspended and NICE will continue to monitor any developments. |
| 31 May 2012 | The manufacturer of ridaforolimus has informed us that they will not provide an evidence submission for this appraisal. NICE has therefore suspended this appraisal. |
For further information on our processes and methods, please see our CHTE processes and methods manual